Genetic variants contributing to daunorubicin-induced cytotoxicity

Cancer Research

Volumn 68, Issue 9, 2008, Pages 3161-3168

  Huang, R Stephanie ^a   Duan, Shiwei ^a   Kistner, Emily O ^a   Bleibel, Wasim K ^a   Delaney, Shannon M ^a   Fackenthal, Donna L ^a   Das, Soma ^a   Dolan, M Eileen ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1B1; DAUNORUBICIN; ANTINEOPLASTIC ANTIBIOTIC; CYP1B1 PROTEIN, HUMAN; CYTOCHROME P450;

ARTICLE; CANCER INHIBITION; CARDIOTOXICITY; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; IC 50; LINEAR REGRESSION ANALYSIS; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; DRUG RESISTANCE; GENETIC LINKAGE; GENETIC PREDISPOSITION; GENETICS; NEOPLASM; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CYTOCHROME P-450 ENZYME SYSTEM; DAUNORUBICIN; DRUG RESISTANCE, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INHIBITORY CONCENTRATION 50; LINKAGE (GENETICS); NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 44849121698     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6381     Document Type: Article

References (50)

1. Davis H, Davis T. Daunorubicin and adriamycin in cancer treatment: an analysis of their roles and limitations. Cancer Treat Rep 1979;63:809-15.
2. Schurmann D, Dormann A, Grunewald T, Ruf B. Successful treatment of AIDS-related pulmonary Kaposi's sarcoma with liposomal daunorubicin. Eur Respir J 1994;7:824-5.
3. Goodman MF, Bessman MJ, Bachur NR. Adriamycin and daunorubicin inhibition of mutant T4 DNA polymerases. Proc Natl Acad Sci U S A 1974;71:1193-6.
4. Bachur N, Yu F, Johnson R, Hickey R, Wu Y, Malkas L. Helicase inhibition by anthracycline anticancer agents. Mol Pharmacol 1992;41:993-8.
5. Booser D, Hortobagyi G. Anthracycline antibiotics in cancer therapy: focus on drug resistance. Drugs 1994;47:223-58.
6. Wojnowski L, Kulle B, Schirmer M, et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005;112:3754-62.
7. Lipshultz S. Exposure to anthracyclines during childhood causes cardiac injury. Semin Oncol 2006;33:S8-14.
8. Seiter K. Toxicity of the topoisomerase II inhibitors. Expert Opin Drug Saf 2005;4:219-34.
9. Young R, Ozols R, Myers C. The anthracycline antineoplastic drugs. N Engl J Med 1981;305:139-53.
10. Shan K, Lincoff M, Young J. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996;125:47-58.
11. Duan S, Bleibel WK, Huang RS, et al. Mapping genes that contribute to daunorubicin-induced cytotoxicity. Cancer Res 2007;67:5425-33.
12. Dasgupta R, Adamson P, Davies F, et al. Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma. Blood 2003;102:2345-50.
13. Naoe T, Tagawa Y, Kiyoi H, et al. Prognostic significance of the null genotype of glutathione S-transferase-T1 in patients with acute myeloid leukemia: increased early death after chemotherapy. Leukemia 2002;16:203-8.
14. Hasan S, Dinh K, Lombardo F, Kark J. Doxorubicin cardiotoxicity in African Americans. J Natl Med Assoc 2004;96:196-9.
15. Huang RS, Duan S, Bleibel WK, et al. A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci U S A 2007;104:9758-63.
16. Huang RS, Duan S, Shukla SJ, et al. Identification of genetic variants contributing to cisplatin-induced cytotoxicity using a genome-wide approach. Am J Hum Genet 2007;81:427-37.
17. Huang RS, Kistner EO, Bleibel WK, Shukla SJ, Dolan ME. Effect of population and gender on chemotherapeutic agent-induced cytotoxicity. Mol Cancer Ther 2007;6:31-6.
18. Abecasis G, Cardon L, Cookson W. A general test of association for quantitative traits in nuclear families. Am J Hum Genet 2000;66:279-92.
19. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995;57:289-300.
20. Dolan ME, Newbold KG, Nagasubramanian R, et al. Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res 2004;64:4353-6.
21. Watters JW, Kraja A, Meucci MA, Province MA, McLeod HL. Genome-wide discovery of loci influencing chemotherapy cytotoxicity. Proc Natl Acad Sci U S A 2004;101:11809-14.
22. Stranger BE, Forrest MS, Clark AG, et al. Genome-wide associations of gene expression variation in humans. PLoS Genet 2005;1:e78.
23. Gyorffy B, Burowiak P, Kiesslich O, et al. Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer 2006;118:1699-712.
24. Goeptar A, Te Koppele J, Lamme E, Pique J, Vermeulen N. Cytochrome P450 2B1-mediated one-electron reduction of adriamycin: a study with rat liver microsomes and purified enzymes. Mol Pharmacol 1993;44:1267-77.
25. Lapucci A, Donnini M, Papucci L, et al. AUF1 is a bcl-2 A + U-rich element-binding protein involved in bcl-2 mRNA destabilization during apoptosis. J Biol Chem 2002;277:16139-46.
26. Shchors K, Yehiely F, Kular R, Kotlo K, Brewer G, Deiss L. Cell death inhibiting RNA (CDIR) derived from a 3′-untranslated region binds AUF1 and heat shock protein 27. J Biol Chem 2002;277:47061-72.
27. Izquierdo M, Neefjes J, Mathari A, Flens M, Scheffer G, Scheper R. Overexpression of the ABC transporter TAP in multidrug-resistant human cancer cell lines. Br J Cancer 1996;74:1961-7.
28. Huxford T, Huang D-B, Malek S, Ghosh G. The crystal structure of the IκBα/NF-κB complex reveals mechanisms of NF-κB inactivation. Cell 1998;95:759.
29. Jacobs MD, Harrison SC. Structure of an IkBa/NF-κB complex. Cell 1998;95:749.
30. Cherbonnier C, Déas O, Carvalho G, et al. Potentiation of tumour apoptosis by human growth hormone via glutathione production and decreased NF-B activity. Br J Cancer 2003;89:1108-15.
31. Cherbonnier C, Deas O, Vassal G, et al. Human growth hormone gene transfer into tumor cells may improve cancer chemotherapy. Cancer Gene Ther 2002;9:497-504.
32. Tergaonkar V, Bottero V, Ikawa M, Li Q, Verma IM. I{κ}B Kinase-Independent I{κ}B{α} degradation pathway: functional NF-{κ}B activity and implications for cancer therapy. Mol Cell Biol 2003;23:8070-83.
33. Buss H, Dorrie A, Schmitz M, Hoffmann E, Resch K, Kracht M. Constitutive and interleukin-1-inducible phosphorylation of p65 NF-{κ}B at serine 536 is mediated by multiple protein kinases including I{κ}B kinase (IKK)-{α}, IKK{β}, IKK{ε}, TRAF family member-associated (TANK)-binding kinase 1 (TBK1), and an unknown kinase and couples p65 to TATA-binding protein-associated factor II31-mediated interleukin-8 transcription. J Biol Chem 2004;279:55633-43.
34. Adli M, Baldwin A. IKK-i/IKKε controls constitutive, cancer cell-associated NF-κB activity via regulation of Ser-536 p65/RelA phosphorylation. J Biol Chem 2006;281:26976-84.
35. Fukushima K, Okai Y, Matsuura S, Tsujimoto H, Endo Y. Molecular cloning of feline lung resistance-related protein (LRP) cDNA and its expression in a feline lymphoma cell line and adriamycin-resistant subline. J Vet Med Sci 2006;68:885-90.
36. Pesic M, Markovic J, Jankovic D, et al. Induced resistance in the human non small cell lung carcinoma (NCI-H460) cell line in vitro by anticancer drugs. J Chemother 2006;18:66-73.
37. Han B, Zhang J. Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2. Curr Med Chem Anticancer Agents 2004;4:31-42.
38. Cheng SH, Lam W, Lee ASK, Fung KP, Wu RSS, Fong WF. Low-level doxorubicin resistance in benzo[a]-pyrene-treated KB-3-1 cells is associated with increased LRP expression and altered subcellular drug distribution. Toxicol Appl Pharmacol 2000;164:134-42.
39. Scheltema JMW, Romijn JC, Steenbrugge GJv, Beck WT, Schröder FH, Mickisch GH. Decreased levels of topoisomerase IIα in human renal cell carcinoma lines resistant to etoposide. J Cancer Res Clin Oncol 1997;123:546-54.
40. Cioca D, Aoki Y, Kiyosawa K. RNA interference is a functional pathway with therapeutic potential in human myeloid leukemia cell lines. Cancer Gene Ther 2003;10:125-33.
41. Brown J, Wouters B. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 1999;59:1391-9.
42. Lowe S, Bodis S, McClatchey A, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-10.
43. Efferth T, Sauerbrey A, Steinbach D, et al. Analysis of single nucleotide polymorphism C3435T of the multidrug resistance gene MDR1 in acute lymphoblastic leukemia. Int J Oncol 2003;23:509-17.
44. Staalesen V, Leirvaag B, Lillehaug JR, Lonning PE. Genetic and epigenetic changes in p21 and p21B do not correlate with resistance to doxorubicin or mitomycin and 5-fluorouracil in locally advanced breast cancer. Clin Cancer Res 2004;10:3438-43.
45. Sturm I, Bosanguet A, Hummel M, Dorken B, Daniel P. In B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis. BMC Cancer 2005;18:105.
46. Cheung V, Conlin L, Weber T, et al. Natural variation in human gene expression assessed in lymphoblastoid cells. Nat Genet 2003;33:422-5.
47. Cheung VG, Spielman RS, Ewens KG, Weber TM, Morley M, Burdick JT. Mapping determinants of human gene expression by regional and genome-wide association. Nature 2005;437:1365-9.
48. Deutsch S, Lyle R, Dermitzakis ET, et al. Gene expression variation and expression quantitative trait mapping of human chromosome 21 genes. Hum Mol Genet 2005;14:3741-9.
49. Monks S, Leonardson A, Zhu H, et al. Genetic inheritance of gene expression in human cell lines. Am J Hum Genet 2004;75:1094-105.
50. Morley M, Molony CM, Weber TM, et al. Genetic analysis of genome-wide variation in human gene expression. Nature 2004;430:743-7.